American Association for Cancer Research
Browse
crc-22-0368-s06.pdf (414.76 kB)

Figure S5 from S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes

Download (414.76 kB)
journal contribution
posted on 2023-04-04, 02:21 authored by Cindy Lin, Laura Garcia-Gerique, Erin E. Bonner, Jerome Mastio, Matthew Rosenwasser, Zachary Cruz, Michael Lawler, Luca Bernabei, Kar Muthumani, Qin Liu, Mortimer Poncz, Thomas Vogl, Marie Törngren, Helena Eriksson, Dan T. Vogl, Dmitry I. Gabrilovich, Yulia Nefedova

BM angiogenesis in tumor-free and MM-bearing mice treated with TQ.

Funding

HHS | NIH | National Cancer Institute (NCI)

Pennsylvania Department of Health (PA DOH)

American Association for Cancer Research (AACR)

Interdisciplinary Center of Clinical Research at the University of Münster

German Research Foundation

Active Biotech (Active Biotech AB)

History

ARTICLE ABSTRACT

We identified a novel mechanism by which myeloid cells promote myeloma progression independently of the adaptive immune system. Specifically, we discovered a novel role of S100A8/S100A9, the most abundant proteins produced by neutrophils and monocytes, in regulation of myeloma progression via promotion of the megakaryocyte expansion and angiogenesis. Tasquinimod, an inhibitor of S100A9, has potent antimyeloma effects as a single agent and in combination with lenalidomide and with proteasome inhibitors.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    Hematological CancersMyelomasTumor MicroenvironmentTranslational ResearchImmunologyMyeloid-derived suppressor cellsAngiogenesisSmall Molecule AgentsProteasome inhibitorsChemotherapyCombination chemotherapyDrug Targets

    Licence

    CC BY

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC